Related Experiment Video
Updated: May 27, 2026
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Signatures of drug sensitivity in nonsmall cell lung cancer
Hua C Gong1, Sean Wang, Gary Mayer
1Department of Research and Development, Prometheus Inc. 9410, Carroll Park Drive, San Diego, CA 92121, USA.
Abstract:
We profiled receptor tyrosine kinase pathway activation and key gene mutations in eight human lung tumor cell lines and 50 human lung tumor tissue samples to define molecular pathways. A panel of eight kinase inhibitors was used to determine whether blocking pathway activation affected the tumor cell growth. The HER1 pathway in HER1 mutant cell lines HCC827 and H1975 were found to be highly activated and sensitive to HER1 inhibition. H1993 is a c-MET amplified cell line showing c-MET and HER1 pathway activation and responsiveness to c-MET inhibitor treatment. IGF-1R pathway activated H358 and A549 cells are sensitive to IGF-1R inhibition. The downstream PI3K inhibitor, BEZ-235, effectively inhibited tumor cell growth in most of the cell lines tested, except the H1993 and H1650 cells, while the MEK inhibitor PD-325901 was effective in blocking the growth of KRAS mutated cell line H1734 but not H358, A549 and H460. Hierarchical clustering of primary tumor samples with the corresponding tumor cell lines based on their pathway signatures revealed similar profiles for HER1, c-MET and IGF-1R pathway activation and predict potential treatment options for the primary tumors based on the tumor cell lines response to the panel of kinase inhibitors.
Insights
This study identifies key receptor tyrosine kinase pathway activations in lung tumors. Targeting these pathways with specific inhibitors shows promise for personalized lung cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Receptor tyrosine kinase (RTK) pathways are crucial in lung cancer development.
- Understanding specific pathway activations and mutations is key for targeted therapy.
Purpose of the Study:
- To profile RTK pathway activation and gene mutations in lung cancer cell lines and tissues.
- To evaluate the efficacy of kinase inhibitors in blocking tumor cell growth.
Main Methods:
- Profiling of RTK pathway activation and gene mutations in 8 lung cancer cell lines and 50 tumor tissues.
- Treatment of cell lines with a panel of 8 kinase inhibitors.
- Hierarchical clustering of pathway signatures from cell lines and primary tumors.
Main Results:
- HER1 pathway highly activated and sensitive to HER1 inhibition in HER1 mutant cell lines (HCC827, H1975).
- c-MET amplified cell line (H1993) showed c-MET and HER1 pathway activation, responding to c-MET inhibitors.
- IGF-1R pathway activated cells (H358, A549) were sensitive to IGF-1R inhibition.
- PI3K inhibitor BEZ-235 inhibited most cell lines, except H1993 and H1650.
- MEK inhibitor PD-325901 effective in KRAS-mutated H1734, but not other cell lines.
Conclusions:
- Lung tumor cell lines and primary tumors share similar RTK pathway activation profiles (HER1, c-MET, IGF-1R).
- Kinase inhibitor responses in cell lines can predict potential treatment options for primary lung tumors.
- This profiling approach aids in defining personalized treatment strategies for lung cancer.